Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Reshaping Tuberculosis Disease Market Vertical with DLI's Drug Insights, Regulatory Consulting, and Clinical Trial Management Services | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

11 Oct, 2023, 14:45 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 11, 2023 /PRNewswire/ -- Tuberculosis is a global health concern affecting a large proportion of the world population. According to epidemiology study by World Health Organization, every day close to 4400 people lose their lives to TB and close to 30,000 people fall ill every single day. This high disease burden is pushing government bodies, healthcare experts, and welfare organizations to emphasize on eradicating or at least minimizing the prevalence of this dreadful ailment.

Tuberculosis (TB) is bacterial infection that predominantly affects the lungs. Mycobacterium tuberculosis is the bacterium responsible for the occurrence of this disease. Apart from the respiratory system TB also starts impacting other organs, leading to severe complications and even death. It is a contagious disorder and TB transmission may occur via the inhalation of droplets that get released in the air when an infected person sneezes, coughs, or even talks.

Continuous R&D activities are being conducted with an aim to develop high advanced tuberculosis treatment solutions. DLI has been a forefront in assisting the players in their drug development endeavours. The Tuberculosis Disease Market players procure DLI's healthcare consulting services to accelerate various activities. DLI helps them with treatment gaps identification, clinical trial feasibility analysis, commercial strategy analysis, drug launch strategies, along with pricing and market access decisions.

Price and Market Access

Tuberculosis Disease- Causes and Symptoms:

As described, this disease is caused by the bacterium Mycobacterium tuberculosis. Apart from that, coming in close contact with infected person, excessive smoking, exposure to environmental irritants, and harmful chemical may also trigger this disorder.

It is worth noting that there is another form of this ailment known as Latent TB infection. Here the bacteria can enter the body but remain dormant, causing no symptoms. Pulmonary TB and extra-pulmonary TB are two other sub types of this disease.

The primary symptoms of TB are persistent cough, fatigue, blood droplets with cough, weight loss, fever and chills, swollen lymph nodes, and shortness of breath, among others. It is advisable to consult a TB specialist when a person experience any of these symptoms for a long duration. Numerous TB clinics have been set up in both rural and urban areas across the globe so as to accelerate TB diagnosis and reduce the risk of complications.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

https://www.diseaselandscape.com/downloadsample/postid/7

Diagnostic and Treatment Landscape:

Early diagnosis of this disease is nothing less than a boon for patients. It not only increases their life span but also reduce the chances of hospitalization. Proper TB healthcare can be provided to the patients if it is diagnosed at its initial stage. TB screening, clinical evaluation, chest x-ray, Mantoux test, sputum culture, and biopsy, among others are some of the efficient diagnostic treatments.

The treatment vertical for this infection is vast. Numerous affordable TB drugs have been introduced to reduce the economic disparity among the masses when it comes to quality healthcare access. Reduced TB treatment costs across various regions are enabling people with low-income levels to easily buy TB medication.  Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), Ethambutol (EMB) are some of the most commonly prescribed TB drugs. It is also worth mentioning that TB prevention is crucial for the people right from an early stage. For that effective TB vaccines have been developed by leading pharma companies that has significantly contributed to the decreased burden of TB worldwide.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

https://www.diseaselandscape.com/checkout?report_id=7

Final Words:

Tuberculosis infection is a menace that has claimed millions of lives worldwide. It took the form of a global health crisis a few decades back. Government bodies and healthcare research organizations made joint efforts to develop effective treatment entities against this ailment. DLI has been offering pharma consulting services to the drug and vaccine developers to help them with product portfolio extension, price reimbursement, product pipeline analysis, and post launch services, among others. With these efforts, they are trying to enhance the quality of life of TB patients and their caregivers.

Browse Through More Infectious Diseases Research Reports.

Related Reports:

Launch of a Medical High-Tech Innovation Case Study

Case Analysis: Development of an Antibiotic

Case Study: Using Emerging Technologies to Discover Antiallergic Drugs

Case Study: Creation and Submission of a New Drug Application (NDA)

Case Study: Trends in API Prices

Collaboration with Commercial Laboratories to Develop Monkeypox Detection Technologies to Support Business Growth

For lung cancer treatment, radiation is employed.

Immunomodulating Drugs for Lupus

To Launch More Affordable Drugs and Boost Productivity Through Cost-Effective Research and Development

Finding a Hemophilia Treatment Facility that Accepts

Launch of a Pneumonia Diagnostic Tool in the Market

Case Study: Clinical Trials for Parkinson's Disease Project Management

Case Study: The Pancreatic Cancer Treatment Landscape is Changing

Case Study: Examining Topical Medicines for Treatment of Psoriasis

Case Study: The Benefits of an Combination for Alzheimer's Drug

Case Study: Vaccine Development

A case study involving the cooperation of a pharmaceutical business with CDMOs and SMOs

Case Study: Expansion of the Australian Product Portfolio

AI application in a healthcare organization: a case study

Case Study: Landscape Analysis of Ovarian Cancer Treatment

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  
Disease Landscape Insights LLP  
6th Floor, Sr No.207, Office A H 6070 Phase 1  
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014.
Sales Contact: +44-2038074155  
Asia Office Contact: +917447409162 
Email: ajay@diseaselandscape.com
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs
Case Study: https://www.diseaselandscape.com/casestudies    
Pharma consulting Services  
Follow Us: LinkedIn | Twitter | Facebook 

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.